JSA advises Levim Lifetech on Eris Lifesciences’ ₹54 crore investment for 30% stake
JSA Advocates & Solicitors advised Levim Lifetech Limited on the sale of a 30% stake to Eris Lifesciences Limited for an investment of ₹54 crore.
The acquisition is aimed at expanding Levim Lifetech’s biotechnology footprint across a wide range of products and technologies, bolstering its innovation-driven growth in the biopharmaceutical space.
Founded in 2007 and headquartered in Ahmedabad, Eris Lifesciences is a publicly listed pharmaceutical company focused on chronic and sub-chronic lifestyle-related therapies, including anti-diabetes, cardiology, nutrition, and neuropsychiatry. In 2021, Eris entered the insulin segment through a joint venture with MJ Biopharm, enhancing its diabetes care portfolio.
Levim Lifetech Pvt. Ltd. is an Indian biotechnology company dedicated to developing and commercializing evidence-based therapies through cutting-edge science.
The JSA team was led by Varun Sriram (Partner), with support from Bharkavi S (Senior Associate) and Associates Nithyashree Venkatesh, Maheema Senthilkumar, and Sudha Putrevu.
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.